NAV

Iopofosine I-131

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Iopofosine I-131
DrugBank Accession Number
DB15244
Background

Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 641.626
Monoisotopic: 641.277345357
Chemical Formula
C29H53INO4P
Synonyms
  • 18-(P-(131I )-IODOPHENYL)OCTADECYL PHOSPHOCHOLINE
  • 18-(p-(131I)-iodophenyl)octadecyl phosphocholine
  • 18-(p-[131]-iodophenyl)octadecyl phosphocholine
  • 2-((HYDROXY((18-(4-(131I)IODOPHENYL)OCTADECYL)OXY)PHOSPHINYL)OXY)-N,N,NTRIMETHYLETHANAMINIUM INNER SALT
  • Ethanaminium, 2-((hydroxy((18-(4-(iodo-131I)phenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner salt
  • I-131-CLR1404
External IDs
  • 131I-CLR1404
  • 131I-NM-404
  • I-131-CLR1404
  • NM-404 I-131
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
R048696O9L
CAS number
873438-88-1
InChI Key
ZOAIEFWMQLYMTF-YRKXUXMHSA-N
InChI
InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3/i30+4
IUPAC Name
18-[4-(¹³¹I)iodophenyl]octadecyl 2-(trimethylazaniumyl)ethyl phosphate
SMILES
C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C([131I])C=C1

References

General References
Not Available
ChemSpider
13173778
ChEMBL
CHEMBL4297495

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCentral Nervous System Lymphoma / Chronic Lymphocytic Leukemia / Diffuse Large B-Cell Lymphoma (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL) / Multiple Myeloma (MM) / Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
2WithdrawnTreatmentGlioma1
1Active Not RecruitingTreatmentChildhood Solid Neoplasm / Diffuse Intrinsic Pontine Gliomas (DIPG) / Ewing's Sarcoma / Neuroblastoma (NB) / Osteosarcoma / Pediatric Brain Tumor / Pediatric Lymphoma / Rhabdomyosarcomas1
1Active Not RecruitingTreatmentHead And Neck Cancer1
1CompletedBasic ScienceSolid Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06e-05 mg/mLALOGPS
logP4.38ALOGPS
logP5.65Chemaxon
logS-7.8ALOGPS
pKa (Strongest Acidic)1.88Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area58.59 Å2Chemaxon
Rotatable Bond Count24Chemaxon
Refractivity172.77 m3·mol-1Chemaxon
Polarizability69.9 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 15:03 / Updated at July 18, 2023 22:57